21154 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
#2TREATMENT METHOD
#3SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES
#4COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
#5TREATMENT METHOD
#6SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES
#7HUMANIZED 3E10 ANTIBODIES, VARIANTS, AND ANTIGEN BINDING FRAGMENTS THEREOF
#8TREATMENT METHOD
#9Activity Modulator
#10CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
#11Anticoagulant compositions and uses thereof
#12NEOANTIGEN ENGINEERING USING SPLICE MODULATING COMPOUNDS
#13METHODS FOR IDENTIFYING BETA-GLUCAN BINDING TO IMMUNE CELLS
#14TREATMENT METHOD
#15Compositions for management of disorders of the gastrointestinal tract
#16Human antibodies, pharmaceutical compositions and methods
#17METHODS AND COMPOSITIONS FOR TREATING DISEASE-RELATED CACHEXIA
#18TREATMENT METHOD
#19Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
#20TANNIN AND ANTI-GLIADIN ANTIBODY COMPOSITIONS FOR TREATMENT OF A DISEASE OF THE INTESTINAL TRACT
#21METHODS FOR PROTECTING HAIR FOLLICLES
#22IMMUNE MOTIFS IN PRODUCTS FROM DOMESTIC ANIMALS
#23PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
#24Anti-isoAsp7 amyloid β (Aβ) antibodies and uses thereof
#25Antihuman PCSK9 monoclonal antibody and application thereof
#26MULTIVALENT FRAGMENTS OF ANTIBODY 3E10 AND METHODS OF USE THEREOF
#27Multi-drug delivery system and uses thereof
#28CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies
#29SURFACE-MODIFIED NANOSPHERES ENCAPSULATING ANTIGEN-BINDING MOLECULES
#30Therapeutic compositions and methods with cytokine signaling immunomodulators
#31Targeting immunotherapy for amyloidosis
#32Methods for improving safety of blood-brain barrier transport
#33COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY
#34ANTIBODIES TO POLYPHOSPHATE DECREASE CLOT FORMATION, DECREASE INFLAMMATION, AND IMPROVE SURVIVAL
#35Antibody against alopecia-inducing substance as antigen, composition and production method
#36Immunoglobulin polypeptide fractions from products of domestic animals
#37PHARMACEUTICAL COMPOSITIONS COMPRISING 0.5 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
#38PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
#39Use of PLL for improving the stability of molecules in solution
#40Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
#41ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE
#42Tannin and anti-gliadin antibody compositions for treatment of a disease of the intestinal tract
#43MULTIVALENT FRAGMENTS OF ANTIBODY 3E10 AND METHODS OF USE THEREOF
#44Targeting immunotherapy for amyloidosis
#45Treatment method
#46Multi-drug delivery system and use thereof
#47Family of Pain Producing Substances and Methods to Produce Novel Analgesic Drugs
#48Treatment of celiac disease, C. difficile infection, food intolerance and food allergy with secretory IgA/IgM
#49Antibody against alopecia-inducing substance as antigen, composition and production method
#50METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT
#51Targeting immunotherapy for amyloidosis
#52Antibody Buffering of a Ligand in Vivo
#53TIM RECEPTORS AS VIRUS ENTRY COFACTORS
#54METHODS FOR IMPROVING SAFETY OF BLOOD-BRAIN BARRIER TRANSPORT
#55Human antibodies to middle east respiratory syndrome—coronavirus spike protein
#56Anti-influenza B virus hemagglutinin antibodies and methods of use
#57Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments
#58ANTICOAGULANT ANTIDOTES
#59ANTAGONIST TO AN ENZYME AND/OR A METABOLITE OF THE KYNURENINE PATHWAY
#60Methods for identifying beta-glucan binding to immune cells
#61Compositions and methods for beta-glucan immunotherapy
#62Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
#63COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASE OR CONDITION
#64Method of treating celiac disease
#65ANTICOAGULANT ANTIDOTES
#66Antibody specific for trans-resveratrol and use thereof
#67FAMILY OF PAIN PRODUCING SUBSTANCES AND METHODS TO PRODUCE NOVEL ANALGESIC DRUGS
#68Humanized, anti-N2 antibodies
#69Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury
#70Phosphorylcholine conjugates and corresponding antibodies
#71Delivery system for cytotoxic drugs by bispecific antibody pretargeting
#72Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
#73Method of treating hypertension disorder and a pharmaceutical agent
#74Method of treating a pathological syndrome and a pharmaceutical agent
#75Method of treating a pathological syndrome and a pharmaceutical agent
#76Antibodies with immune effector activity and that internalize in endosialin-positive cells
#77METHODS OF TARGETING CELLS FOR DIAGNOSIS AND THERAPY
#78Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof
#79Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
#80PHOSPHORYCHOLINE CONJUGATES AND CORRESPONDING ANTIBODIES
#81Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds
#82Family of pain producing substances and methods to produce novel analgesic drugs
#83Treatment of celiac disease with IgA
#84Methods of diagnosing and treating fibrosis
#85Compositions, methods and animal models for screening therapeutics for TH2-type disease
#86Method for administering homeopathically potentiated antibodies against mediator of inflammation
#87METHOD AND KIT FOR TREATING NICOTINE ADDICTION
#88Method of treating disorders of the cardiovascular system and a pharmaceutical agent
#89Method of treating a pathological syndrome and a pharmaceutical agent
#90Method of treating a disorder or condition of viral etiology
#91Method for administering homeopathically potentized antibody
#92Antibodies with immune effector activity and that internalize in endosialin-positive cells
#93METHODS OF TARGETING CELLS FOR DIAGNOSIS AND THERAPY
#94Method of treating a pathological syndrome and a pharmaceutical agent
#95Method of treating a pathological syndrome and a pharmaceutical agent
#96Method of treating a pathological syndrome and a pharmaceutical agent
#97Method of treating a pathological syndrome and a pharmaceutical agent
#98Method of treating a pathological syndrome and a pharmaceutical agent
#99Phosphorylcholine conjugates and corresponding antibodies
#100Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
#101Method of treating a pathological syndrome and a pharmaceutical agent
#102Antibodies with immune effector activity and that internalize in endosialin-positive cells
#103Antibody buffering of a ligand in vivo
#104Methods and compositions for treating osteoarthritis